FENC — Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Q2 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Sales: $9.7 million, a 33% increase year-over-year and a 10% increase sequentially, marking the highest quarterly sales in the company's history.
• Growth Trend: This quarter represents the third consecutive quarter of sequential growth in net product sales, attributed to a revamped go-to-market strategy and the addition of 14 new accounts.
• Operating Expenses: Total cash operating expenses were approximately $11 million, up $2 million from Q1 2025, driven by increased marketing and headcount costs. Selling and marketing expenses were $4.4 million, while G&A expenses were $7 million.
• Cash Position: Cash and cash equivalents stood at approximately $18.7 million as of June 30, 2025. The company anticipates full-year cash operating expenses to be similar to 2024, around $33 million.

2. Strategic Updates and Business Highlights

• Product Awareness and Adoption: Fennec has made significant strides in increasing awareness of PEDMARK, the only FDA-approved therapy for preventing cisplatin-induced ototoxicity (CIO), through educational campaigns and presence at major conferences.
• Formulary Additions: A large national oncology group has added PEDMARK to its formulary for patients under 40, indicating growing recognition of the need for CIO prevention.
• Advisory Boards: Multiple advisory boards with leading academic centers were held to align strategies for diagnosing and managing CIO.
• Patient Assistance Program: The Fennec HEARS program has seen quarter-over-quarter growth in enrollment, enhancing patient access and support.

3. Forward Guidance and Outlook

• Q3 Expectations: The company expects continued growth in Q3, particularly from the newly activated accounts and ongoing efforts to establish PEDMARK as the standard of care for CIO prevention.
• Norgine Partnership: The launch of PEDMARQSI in the EU is progressing well, with expectations for additional updates on milestones and royalties in the coming quarters.
• Long-term Growth: Fennec is optimistic about achieving cash profitability as product revenues increase and expenses decrease in the second half of 2025.

4. Bad News, Challenges, or Points of Concern

• Operating Expense Increase: The rise in operating expenses, particularly in marketing and G&A, may raise concerns about financial sustainability if not matched by revenue growth.
• Regulatory and Competitive Risks: The company faces challenges related to compliance with FDA guidance against substituting PEDMARK with compounded versions, and ongoing litigation related to intellectual property could impact financials.
• Market Penetration: While there is momentum, the company needs to ensure that the growth in new accounts translates into significant patient treatment volumes, particularly in the AYA (adolescent and young adult) segment.

5. Notable Q&A Insights

• Active Prescribers: The company refrained from disclosing specific numbers of active prescribers but highlighted the significant market opportunity in the AYA segment, estimating around 20,000 patients treated with cisplatin.
• EU Market Expansion: The Norgine partnership is expected to expand into additional EU markets early next year, with positive initial traction reported in the UK and Germany.
• FDA Compliance: The FDA has been supportive in ensuring that PEDMARK is used over compounded alternatives, which remains a critical focus in discussions with healthcare providers.
• Future Plans in Japan: The company is in discussions regarding regulatory strategies for the Japanese market, which represents a significant opportunity, especially for pediatric indications.

Overall, Fennec Pharmaceuticals is demonstrating strong revenue growth and strategic execution, while also navigating challenges related to expenses and market penetration. The outlook remains positive, with expectations for continued growth and expansion in both domestic and international markets.